Bausch + Lomb Recalls enVista Intraocular Lenses Due to Inflammatory Complications
Key Insights
Bausch + Lomb (search) has issued a voluntary recall of all enVista (search) platform intraocular lenses (search) in the U.S. after reports of toxic anterior segment syndrome (search) (TASS (search)), an acute inflammatory reaction following cataract (search) surgery.
The recall affects multiple models including enVista Aspire (search), enVista Envy (search), and certain enVista monofocal (search) lenses, with the company citing patient safety as their primary concern despite the complications affecting only 1-2% of implanted lenses.
All reported TASS (search) cases responded well to treatment without requiring lens removal, and the company is investigating the root cause while planning to eventually return the enVista (search) platform to market.
Bausch + Lomb (search) has announced a voluntary recall of its entire enVista (search) platform of intraocular lenses (search) (IOLs) in the United States due to reports of post-surgical inflammatory complications. The recall affects all lots of multiple lens models used in cataract (search) surgery, including enVista Aspire (search), enVista Aspire Toric, enVista Envy (search), enVista Envy Toric, as well as enVista monofocal (search) and enVista monofocal Toric lenses.
The company initiated the recall after receiving an increased number of reports of toxic anterior segment syndrome (search) (TASS (search)), an acute sterile inflammatory reaction in the anterior chamber of the eye. TASS typically develops within 12 to 48 hours following cataract (search) surgery and can cause significant discomfort and potential complications if left untreated.
"As much as we believe in the enVista (search) platform, patient safety will always be our number one priority," said Brent Saunders, chairman and CEO of Bausch + Lomb (search), in a statement. "Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust."
Understanding TASS and Its Impact
Toxic anterior segment syndrome (search) is a known potential complication of any cataract (search) surgery that can have various causes, including residual cleaning agents, bacterial endotoxins, or other contaminants introduced during the surgical procedure. The condition presents as inflammation inside the eye and requires prompt medical attention.
According to Bausch + Lomb (search), all patients who developed TASS (search) in connection with the enVista (search) lenses responded quickly to treatment, and none required removal of the implanted lenses. The company reports that the affected lenses represent only approximately 1-2 percent of all implanted enVista lenses, suggesting this is a relatively rare occurrence.
The company is currently investigating the root cause of these complications but decided to issue the recall as a precautionary measure while the investigation continues.
Recommendations for Patients and Healthcare Providers
Patients who have recently undergone cataract (search) surgery with enVista (search) lenses should be vigilant for symptoms of TASS (search), which may include:
- Eye pain or discomfort
- Decreased vision
- Redness
- Light sensitivity
Bausch + Lomb (search) advises patients experiencing any of these symptoms to contact their eye care professional immediately. For healthcare providers, the company recommends:
- Closely monitoring cataract surgery patients for at least 48 hours post-procedure
- Instructing patients to report any new or worsening symptoms immediately
- Following established protocols for treating TASS if it occurs
- Discontinuing use of all recalled enVista lenses
Cataract Surgery and Intraocular Lenses
Cataract (search) surgery is one of the most common surgical procedures performed worldwide, with approximately 4 million procedures conducted annually in the United States alone. During the procedure, the eye's cloudy natural lens is removed and replaced with an artificial intraocular lens.
The enVista (search) platform includes several advanced IOL options designed to provide improved visual outcomes for patients undergoing cataract (search) surgery. These lenses are manufactured with specific features to address various visual needs, including astigmatism correction in the toric models.
Company Response and Future Plans
Despite the recall, Bausch + Lomb (search) has expressed confidence in the overall safety profile of the enVista (search) platform, noting that the vast majority of patients have experienced successful outcomes with these lenses.
"These reports represent an extremely small percentage of implanted lenses, with a positive prognosis for everyone involved," Saunders stated. "We look forward to identifying a root cause and bringing the enVista (search) platform back to market."
The company has begun communicating with eye care professionals about the recall, providing information on affected lots and return protocols. Bausch + Lomb (search) has not provided a timeline for when the enVista (search) platform might return to the market, as this will depend on the findings of their ongoing investigation.
Industry Context
This recall comes at a time when the ophthalmic device market is highly competitive, with several major manufacturers offering advanced IOL technologies. Bausch + Lomb (search), with its long history in eye care dating back to 1853, remains one of the leading global companies in the field with approximately 13,500 employees and operations in about 100 countries.
The company's prompt voluntary recall demonstrates the industry's commitment to patient safety, even when complications affect a relatively small percentage of devices. Such recalls, while disruptive in the short term, are essential to maintaining trust in medical devices and ensuring optimal patient outcomes.
Healthcare providers with questions about the recall can contact Bausch + Lomb (search) directly or visit the FDA's recall notification page for additional information.